Alveolus Biomedical

Alveolus Biomedical is a clinical-stage biotechnology company focused on developing regenerative cell therapies for severe respiratory diseases. The company utilizes a proprietary platform to produce and deliver Alveolar Type II (ATII) cells, which are essential for lung repair and surfactant production. Their primary therapeutic targets include Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), and neonatal respiratory conditions. By restoring the lung's natural regenerative capacity, Alveolus aims to reduce mortality and improve long-term outcomes for patients with acute and chronic pulmonary failure. The company's approach represents a shift from managing symptoms to actively repairing damaged lung tissue.